Drug intelligence / Profile preview

Tosymra (sumatriptan)

Development stage
Approved
Lead developer
Dr. Reddy's Laboratories
Modality
Small Molecules
Administration
Intranasal
01

Overview

Sumatriptan (brand name: **Tosymra**) is a small molecule **serotonin (5-HT1B/1D) receptor agonist** (a member of the triptan class) developed as a rapid-acting, single-dose **nasal spray** formulation for the **acute treatment of migraine attacks with or without aura in adults**. Tosymra is formulated with the absorption enhancer Intravail to provide systemic drug levels comparable to subcutaneous injection, resulting in rapid onset of action. It is not used to prevent migraines, nor is it indicated for cluster, hemiplegic, or basilar migraines. The main mechanism involves cranial blood vessel constriction and inhibition of pro-inflammatory neuropeptide release through selective activation of 5-HT1B/1D receptors on intracranial blood vessels and trigeminal sensory nerves.

Brand names
Tosymra
Other names
sumatriptan nasal spray
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR1E (5-hydroxytryptamine receptor 1E)HTR1F (Serotonin 5-HT1F receptor)

Beyond the preview

Go deeper on Tosymra (sumatriptan).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tosymra (sumatriptan).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call